-
1
-
-
0029976967
-
Cytomegalovirus prophylaxis in solid organ transplant recipients
-
DOI 10.1097/00007890-199605150-00001
-
Patel R, Snydman DR, Rubin RH et al.: Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61, 1279-1289 (1996). (Pubitemid 26155045)
-
(1996)
Transplantation
, vol.61
, Issue.9
, pp. 1279-1289
-
-
Patel, R.1
Snydman, D.R.2
Rubin, R.H.3
Ho, M.4
Pescovitz, M.5
Martin, M.6
Paya, C.V.7
-
2
-
-
0029782102
-
Cytomegalovirus infection following liver transplantation: Review of the literature
-
Kanj SS, Sharara AI, Clavien PA, Hamilton JD: Cytomegalovirus infection following liver transplantation: review of the literature. Clin. Infect. Dis. 22, 537-549 (1996). (Pubitemid 26259186)
-
(1996)
Clinical Infectious Diseases
, vol.22
, Issue.3
, pp. 537-549
-
-
Kanj, S.S.1
Sharara, A.I.2
Clavien, P.-A.3
Hamilton, J.D.4
-
3
-
-
0028353446
-
Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: A trial of ganciclovir vs immunoglobulin
-
Conti DJ, Freed BM, Gruber SA, Lempert N: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch. Surg. 129, 443-447 (1994). (Pubitemid 24115966)
-
(1994)
Archives of Surgery
, vol.129
, Issue.4
, pp. 443-447
-
-
Conti, D.J.1
Freed, B.M.2
Gruber, S.A.3
Lempert, N.4
-
4
-
-
0024361608
-
A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
-
Balfour J, Henry H, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320(21), 1381-1388 (1989). (Pubitemid 19138933)
-
(1989)
New England Journal of Medicine
, vol.320
, Issue.21
, pp. 1381-1387
-
-
Balfour Jr., H.H.1
Chace, B.A.2
Stapleton, J.T.3
Simmons, R.L.4
Fryd, D.S.5
-
5
-
-
0033551348
-
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group
-
Lowance D, Neumayer HH, Legendre CM et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999).
-
(1999)
N. Engl. J. Med.
, vol.340
, Issue.19
, pp. 1462-1470
-
-
Lowance, D.1
Neumayer, H.H.2
Legendre, C.M.3
-
6
-
-
0031581506
-
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
-
The Oral Ganciclovir International Transplantation Study Group [corrected]
-
Gane E, Saliba F, Valdecasas GJ et al.: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350(9093), 1729-1733 (1997).
-
(1997)
Lancet
, vol.350
, Issue.9093
, pp. 1729-1733
-
-
Gane, E.1
Saliba, F.2
Valdecasas, G.J.3
-
7
-
-
1942469969
-
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
-
Paya C, Humar A, Dominguez E et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
-
(2004)
Am. J. Transplant.
, vol.4
, Issue.4
, pp. 611-620
-
-
Paya, C.1
Humar, A.2
Dominguez, E.3
-
9
-
-
0024041143
-
Antiviral activity and mechanism of action of ganciclovir
-
Matthews T, Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3), S490-S494 (1988).
-
(1988)
Rev. Infect. Dis.
, vol.10
, Issue.SUPPL. 3
-
-
Matthews, T.1
Boehme, R.2
-
11
-
-
0036137356
-
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
-
Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185(1), 20-27 (2002).
-
(2002)
J. Infect. Dis.
, vol.185
, Issue.1
, pp. 20-27
-
-
Limaye, A.P.1
Raghu, G.2
Koelle, D.M.3
Ferrenberg, J.4
Huang, M.L.5
Boeckh, M.6
-
12
-
-
0034686916
-
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
-
Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356(9230), 645-649 (2000).
-
(2000)
Lancet
, vol.356
, Issue.9230
, pp. 645-649
-
-
Limaye, A.P.1
Corey, L.2
Koelle, D.M.3
Davis, C.L.4
Boeckh, M.5
-
13
-
-
0032573205
-
Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function
-
Pescovitz MD, Pruett TL, Gonwa T et al.: Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 66, 1104-1107 (1998).
-
(1998)
Transplantation
, vol.66
, pp. 1104-1107
-
-
Pescovitz, M.D.1
Pruett, T.L.2
Gonwa, T.3
-
14
-
-
0033801280
-
Membrane transporters
-
Lee VH: Membrane transporters. Eur. J. Pharm. Sci. 11(Suppl. 2), S41-S50 (2000).
-
(2000)
Eur. J. Pharm. Sci.
, vol.11
, Issue.SUPPL. 2
-
-
Lee, V.H.1
-
15
-
-
0032546467
-
Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2
-
Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH: Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 19, 470-475 (1998).
-
(1998)
Biochem. Biophys. Res. Commun.
, vol.19
, pp. 470-475
-
-
Ganapathy, M.E.1
Huang, W.2
Wang, H.3
Ganapathy, V.4
Leibach, F.H.5
-
16
-
-
0031981201
-
Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats
-
Sinko PJ, Balimane PV: Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm. Drug Dispos. 19, 209-217 (1998).
-
(1998)
Biopharm. Drug Dispos.
, vol.19
, pp. 209-217
-
-
Sinko, P.J.1
Balimane, P.V.2
-
17
-
-
47649088674
-
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
-
Chou S: Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18(4), 233-246 (2008).
-
(2008)
Rev. Med. Virol.
, vol.18
, Issue.4
, pp. 233-246
-
-
Chou, S.1
-
18
-
-
0036628639
-
Stability of valganciclovir in an extemporaneously compounded oral liquid
-
Anaizi NH, Dentinger PJ, Swenson CF: Stability of valganciclovir in an extemporaneously compounded oral liquid. Am. J. Health Syst. Pharm. 59(13), 1267-1270 (2002).
-
(2002)
Am. J. Health Syst. Pharm.
, vol.59
, Issue.13
, pp. 1267-1270
-
-
Anaizi, N.H.1
Dentinger, P.J.2
Swenson, C.F.3
-
19
-
-
37049016433
-
Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation
-
Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR: Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant. Proc. 39(10), 3111-3116 (2007).
-
(2007)
Transplant. Proc.
, vol.39
, Issue.10
, pp. 3111-3116
-
-
Pescovitz, M.D.1
Jain, A.2
Robson, R.3
Mulgaonkar, S.4
Freeman, R.5
Bouw, M.R.6
-
20
-
-
33645110301
-
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
-
Park JM, Lake KD, Arenas JD, Fontana RJ: Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl. 12, 112-116 (2005).
-
(2005)
Liver Transpl.
, vol.12
, pp. 112-116
-
-
Park, J.M.1
Lake, K.D.2
Arenas, J.D.3
Fontana, R.J.4
-
21
-
-
26444437323
-
Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
-
Jain A, Orloff M, Kashyap R et al.: Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant. Proc. 37(7), 3182-3186 (2005).
-
(2005)
Transplant. Proc.
, vol.37
, Issue.7
, pp. 3182-3186
-
-
Jain, A.1
Orloff, M.2
Kashyap, R.3
-
22
-
-
65849405940
-
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy
-
Kalil AC, Freifeld AG, Lyden ER, Stoner JA: Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE 4(5), E5512 (2009).
-
(2009)
PLoS ONE
, vol.4
, Issue.5
-
-
Kalil, A.C.1
Freifeld, A.G.2
Lyden, E.R.3
Stoner, J.A.4
-
23
-
-
77950468641
-
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients
-
In press
-
Humar A, Lebranchu Y, Vincenti F et al.: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. (2010) (In press).
-
(2010)
Am. J. Transplant.
-
-
Humar, A.1
Lebranchu, Y.2
Vincenti, F.3
-
24
-
-
65249181619
-
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
-
Asberg A, Humar A, Jardine AG et al.: Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transplant. 9(5), 1205-1213 (2009).
-
(2009)
Am. J. Transplant.
, vol.9
, Issue.5
, pp. 1205-1213
-
-
Asberg, A.1
Humar, A.2
Jardine, A.G.3
-
25
-
-
34547829434
-
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
-
Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7(9), 2106-2113 (2007).
-
(2007)
Am. J. Transplant.
, vol.7
, Issue.9
, pp. 2106-2113
-
-
Asberg, A.1
Humar, A.2
Rollag, H.3
-
26
-
-
2442648883
-
Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients
-
Clark BS, Chang IF, Karpen SJ et al.: Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 77(9), 1480 (2004).
-
(2004)
Transplantation
, vol.77
, Issue.9
, pp. 1480
-
-
Clark, B.S.1
Chang, I.F.2
Karpen, S.J.3
-
27
-
-
10744221566
-
Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs
-
Danziger-Isakov LA, Faro A, Sweet S et al.: Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs. Pediatr. Transplant. 7(6), 469-473 (2003).
-
(2003)
Pediatr. Transplant.
, vol.7
, Issue.6
, pp. 469-473
-
-
Danziger-Isakov, L.A.1
Faro, A.2
Sweet, S.3
-
28
-
-
34147102808
-
Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children
-
Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G: Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr. Transplant. 11(3), 301-305 (2007).
-
(2007)
Pediatr. Transplant.
, vol.11
, Issue.3
, pp. 301-305
-
-
Vethamuthu, J.1
Feber, J.2
Chretien, A.3
Lampe, D.4
Filler, G.5
-
29
-
-
0033807143
-
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
-
Pescovitz MD, Rabkin J, Merion RM et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44(10), 2811-2815 (2000).
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, Issue.10
, pp. 2811-2815
-
-
Pescovitz, M.D.1
Rabkin, J.2
Merion, R.M.3
-
30
-
-
67650251911
-
Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients
-
Zhao W, Baudouin V, Zhang D, Deschenes G, Guellec CL, Jacqz-Aigrain E: Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin. Pharmacokinet. 48(5), 321-328 (2009).
-
(2009)
Clin. Pharmacokinet.
, vol.48
, Issue.5
, pp. 321-328
-
-
Zhao, W.1
Baudouin, V.2
Zhang, D.3
Deschenes, G.4
Guellec, C.L.5
Jacqz-Aigrain, E.6
-
31
-
-
77950510829
-
Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
-
DOI:10.1111/j.1399-3062.2009.00478.x Epub ahead of print
-
Pescovitz MD, Ettenger RB, Strife CF et al.: Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl. Infect. Dis. DOI:10.1111/j.1399-3062.2009. 00478.x (2010) (Epub ahead of print).
-
(2010)
Transpl. Infect. Dis.
-
-
Pescovitz, M.D.1
Ettenger, R.B.2
Strife, C.F.3
-
32
-
-
60749110137
-
Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients
-
Vaudry W, Ettenger R, Jara P et al.: Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am. J. Transplant. 9(3), 636-643 (2009).
-
(2009)
Am. J. Transplant.
, vol.9
, Issue.3
, pp. 636-643
-
-
Vaudry, W.1
Ettenger, R.2
Jara, P.3
-
33
-
-
20544469697
-
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients
-
Wiltshire H, Paya CV, Pescovitz MD et al.: Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79(11), 1477-1483 (2005).
-
(2005)
Transplantation
, vol.79
, Issue.11
, pp. 1477-1483
-
-
Wiltshire, H.1
Paya, C.V.2
Pescovitz, M.D.3
-
34
-
-
21144452373
-
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients
-
Wiltshire H, Hirankarn S, Farrell C et al.: Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet. 44(5), 495-507 (2005).
-
(2005)
Clin. Pharmacokinet.
, vol.44
, Issue.5
, pp. 495-507
-
-
Wiltshire, H.1
Hirankarn, S.2
Farrell, C.3
-
35
-
-
49649097948
-
Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus
-
Hierro L, Diez-Dorado R, Diaz C et al.: Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl. 14(8), 1185-1193 (2008).
-
(2008)
Liver Transpl.
, vol.14
, Issue.8
, pp. 1185-1193
-
-
Hierro, L.1
Diez-Dorado, R.2
Diaz, C.3
-
36
-
-
64349090453
-
Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: Preliminary report
-
Venturi C, Bueno J, Gavalda J et al.: Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant. Proc. 41(3), 1038-1040 (2009).
-
(2009)
Transplant. Proc.
, vol.41
, Issue.3
, pp. 1038-1040
-
-
Venturi, C.1
Bueno, J.2
Gavalda, J.3
-
37
-
-
0035008468
-
The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation
-
Green M, Reyes J, Webber S, Rowe D: The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl. Infect. Dis. 3(2), 97-103 (2001).
-
(2001)
Transpl. Infect. Dis.
, vol.3
, Issue.2
, pp. 97-103
-
-
Green, M.1
Reyes, J.2
Webber, S.3
Rowe, D.4
-
38
-
-
32344451537
-
Neurotoxicity related to valganciclovir in a child with impaired renal function: Usefulness of therapeutic drug monitoring
-
Peyriere H, Jeziorsky E, Jalabert A et al.: Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann. Pharmacother. 40(1), 143-146 (2006).
-
(2006)
Ann. Pharmacother.
, vol.40
, Issue.1
, pp. 143-146
-
-
Peyriere, H.1
Jeziorsky, E.2
Jalabert, A.3
-
39
-
-
0030824419
-
Ganciclovir induces reproductive hazards in male rats after short-term exposure
-
Faqi AS, Klug A, Merker HJ, Chahoud I: Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum. Exp. Toxicol. 16(9), 505-511 (1997).
-
(1997)
Hum. Exp. Toxicol.
, vol.16
, Issue.9
, pp. 505-511
-
-
Faqi, A.S.1
Klug, A.2
Merker, H.J.3
Chahoud, I.4
|